The government of the United Kingdom reported in a press release that it has secured early access to 90 million doses of 2 promising vaccine candidates from Novavax and Janssen Pharmaceutical Companies of Johnson and Johnson. As part of this initiative, the UK will support an effort to offer infrastructure for American biotech firm Novavax in running a Phase 3 clinical trial in the UK and plans to manufacture this vaccine in the UK with FUJIFILM Diosynth Biotechnologies. As part of the Janssen deal, the UK government will co-found global clinical trials using their vaccine. The UK government has now secured access to six different vaccine candidates as an element in a multi-pronged strategy to leverage a vaccine portfolio to ensure access should any prove to be safe and effective.
TrialSite Summarizes this latest material update from the UK.
With the latest announcements, how many vaccine candidates does the UK have access to?
Six different vaccine candidates across four different vaccine types, which reflects the government’s strategy to ensure that the UK has a supply of vaccines that are deemed safe and effective.
What are the six products?
· Oxford (AstraZeneca)
· BioNTech/Pfizer (Project Lightspeed)
· GSK/Sanofi Pasteur
· AstraZeneca (antibodies)
How many doses of experimental vaccine has the UK government secured?
With new “in-principal” agreements, the government secured 60 million doses of the Novavax vaccine and 30 million doses from Janssen (known as Ad26.COV.S).
What is the deal here? What does the UK give?
Money. They have agreed to “co-fund” what they term a “ground-breaking global clinical study” of Ad26.COV.S.
When does the next phase of the Ad26.COV.S occur?
Sometime later this year, to investigate if two doses of the vaccine afford long-term protection against SARS-CoV-2.
What is the cost of Ad26.COV.S during the pandemic to people of the UK?
Janssen will make it available on a not-for-profit basis during the emergency pandemic to the UK and the rest of the world to ensure the global supply and equitable access of the vaccine.
How about Novavax? How will they collaborate with the UK?
The UK government, via the National Institute for Health Research (NIHR), will support Novavax
How will Novavax manufacture the vaccine candidate?
They will partner with Diosynth Biotechnologies and their facilities in Billingham, Stockton-on-Tees. Hence the investigational product will be available in Britain.
What are the estimated dates the vaccines could be on the market?
If both vaccines are deemed safe and successful in the clinical trial, they could be delivered to the UK in mid-2021.
Who would have first access in the UK?
Priority groups such as frontline health and social workers, ethnic minorities at risk, elderly, etc.
Does the UK Government provide a clearinghouse of information?
The government launched the NHS COVID-19 vaccine research registry enabling UK residents to sign up and tap into updated information about COVID-19 vaccine trials.